March 06, 2026

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo

Conexiant

March 05, 2026

Hidden Risk: Clinician Substance Use

Longitudinal Swedish study finds physicians and nurses reporting problem drinking or illicit drug use had about twice the risk of rating their care as poor 1 year later

Conexiant

March 05, 2026

Medical Oddities: The Calmest Move in Cardiology?

Yoga for SVT, romantic brain bias, dog-made air chemistry, math learning clues, selenium tea, and glaucoma pillows—medicine’s weekly roundup of strange.

Conexiant

March 05, 2026

Why One Number Isn’t Enough for Patients

Adding a comparison number may help patients interpret risk and make better decisions.

Conexiant

March 05, 2026

Comparing Brain Stimulation Strategies for Depression

Two transcranial magnetic stimulation protocols produced different short-term outcomes in patients with major depressive disorder

Conexiant

March 05, 2026

Do Suicide Efforts for Autism Start Too Late?

A UK survey identifies priorities for suicide prevention, highlighting the need for earlier support, improved diagnostic access, and community-informed services.

Conexiant

March 04, 2026

Could This Tool Reduce Antidepressant Dropout?

The PETRUSHKA platform uses clinical data and patient-reported side-effect priorities to rank antidepressant options and guide shared treatment decisions.

Conexiant

February 27, 2026

Can Testosterone Affect Cognitive Function? 

Systematic review finds modest, population-dependent effects on mood and cognition in adult men 

Conexiant

February 27, 2026

Digital CBT Outperforms Psychoeducation in Generalized Anxiety Disorder 

Participants receiving digital cognitive behavioral therapy had higher remission rates and lower anxiety severity than those assigned to psychoeducation 

Conexiant

February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant